Status and phase
Conditions
Treatments
About
Full description
The study hypothesis is that apixaban will be superior to rivaroxaban with respect to safety using the International Society of Thrombosis and Haemostasis (ISTH) definition of major bleeding and at least non-inferior with respect to efficacy among patients with atrial fibrillation (AF) or atrial flutter (AFL), henceforth noted collectively as "AF". This pragmatic, point-of-care trial will enroll approximately 10,000 Veterans >=age 65 years with AF and a CHA2DS2-VASc score >=3 and randomize them to receive apixaban or rivaroxaban in a 1:1 allocation.
Co-Primary Objectives: Determine in VA trial participants >=age 65 years with non-valvular AF whether oral anticoagulation with apixaban is:
Secondary Objectives:
Co-Primary Endpoints:
Secondary Endpoints (hierarchically ranked):
The estimated number of enrollees will be 10,000 Veterans from approximately 100 VA Medical Centers throughout the U.S.; broad geographical representation in every region is anticipated. Efforts will be made to recruit female Veterans as well as Veterans from diverse racial and ethnic backgrounds with representation of both academic tertiary urban centers and rural community-based outpatient clinics (CBOCs). Strong consideration will be given to selecting enrolling sites based on their prior experience with ambulatory cardiac monitors and, in particular, the 14-day patch monitor (Ziopatch XT), since sites must participate in both the Screening and Treatment Trials. The study will not include enrolling sites outside the U.S.
The primary analysis will comprise Veterans >=65 years, with AF or atrial flutter and CHA2DS2-VASc score >=3. Patients already taking OACs (warfarin or any DOAC) for AF will be eligible. Those on single or dual antiplatelet agents will also be eligible.
Study participants will be randomized to twice daily oral administration of apixaban 5mg or daily oral administration of rivaroxaban 20mg. Reduced dose apixaban (2.5 mg twice daily) will be given to participants who meet 2 of the 3 criteria: age 80 years, body weight 60 kg, and serum creatinine 1.5 mg/dL. Reduced dose rivaroxaban (15 mg once daily) will be given to participants with a creatinine clearance 15-50 mL/min.
The study is planned for 3 years of active enrollment and at least 3 years of remote follow-up of the last enrolled participant, thus 6 years of data collection, with an additional year to completion of data analysis: 7 years (84 months) total.
Enrollment and initiation of anticoagulant will take less than one month for most patients, and up to 90 days for patients randomized to switch to a different OAC who recently received a 90-day supply of their current medication. After randomization to either apixaban or rivaroxaban, all clinical management is per the participants' providers, and all electronic data are collected remotely.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study; notably use of antiplatelet agents or prior OAC use will not be an exclusion criterion:
Primary purpose
Allocation
Interventional model
Masking
10,000 participants in 2 patient groups
Loading...
Central trial contact
Mustabeen Ashfaq, MS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal